These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Antioxidant and acetylcholinesterase inhibitory activities of leaf extract and fractions of Albizia adianthifolia (Schumach) W.F. Wright.
    Author: Sonibare MA, Ayoola IO, Elufioye TO.
    Journal: J Basic Clin Physiol Pharmacol; 2017 Mar 01; 28(2):143-148. PubMed ID: 27658138.
    Abstract:
    BACKGROUND: This study was conducted to determine the antioxidant and acetylcholinesterase inhibitory activities of the leaf extract and different fractions of Albizia adianthifolia (Schumach.) W. Wright, and also to identify and quantify some phenolic compounds in the extract. METHODS: The antioxidant and acetylcholinesterase inhibitory activities of the methanol extract (CME), ethyl acetate (EAF), chloroform (CHF), and n-hexane (NHF) fractions of A. adianthifolia leaves were subjected to in vitro chemical analyses. RESULTS: Phytochemical screening revealed important classes of secondary metabolites. All extracts showed good antioxidant and acetylcholinesterase inhibitory activities. The EAF and CHF gave the highest total phenolic contents of 18.02±0.14 and 18.43±0.95 mg gallic acid equivalent per gram of extract, respectively. The polar extracts gave the highest activity in both assays with lower IC50 values. In the 2,2-diphenyl-1-picrylhydrazyl free-radical scavenging activity assay, the IC50 values of CME, EAF, CHF, and NHF were 77.74±0.84, 55.76±2.30, 58.47±0.72, and 232.24±2.70 µg/mL, respectively, while in the acetylcholinesterase inhibitory assay, the IC50 values of CME, EAF, CHF, and NHF were 11.80±0.88, 10.04±1.67, 17.44±1.74, and 124.38±1.51 µg/mL, respectively. CONCLUSIONS: The results of this study suggest that the leaf of A. adianthifolia could serve as a potential candidate for future search of antioxidant and acetylcholinesterase inhibitors for the management of neurodegenerative disorders such as Alzheimer's disease.
    [Abstract] [Full Text] [Related] [New Search]